Startseite Crystal structure of (Z)-3-(adamantan-1-yl)-1-(3-chlorophenyl)-S-benzylisothiourea, C24H27ClN2S
Artikel Open Access

Crystal structure of (Z)-3-(adamantan-1-yl)-1-(3-chlorophenyl)-S-benzylisothiourea, C24H27ClN2S

  • Ali A. El-Emam EMAIL logo , Fatmah A. M. Al-Omary , Lamees S. Al-Rasheed , Hazem A. Ghabbour und Ebtehal S. Al-Abdullah
Veröffentlicht/Copyright: 23. März 2017
Artikel downloaden (PDF)
Veröffentlichen auch Sie bei De Gruyter Brill
Manuskript einreichen Informationen für Autor*innen
Zeitschrift für Kristallographie - New Crystal Structures
Aus der Zeitschrift Zeitschrift für Kristallographie - New Crystal Structures Band 232 Heft 3

Abstract

C24H27ClN2S, triclinic P1̅ (no. 2), a = 7.1670(3) Å, b = 12.2734(6) Å, c = 13.1560(6) Å, α = 109.605(2)°, β = 96.515(2)°, γ = 97.312(2)°, V = 1066.08(8) Å3, Z = 2, Rgt(F) = 0.0515, wRref(F2) = 0.1396, T = 296(2) K.

CCDC no.:: 1508599

The asymmetric unit of the title crystal structure is shown in the figure. Tables 1 and 2 contain details on crystal structure and measurement conditions and a list of the atoms including atomic coordinates and displacement parameters.

Table 1

Data collection and handling.

Crystal:Colourless block
Size:0.45 × 0.42 × 0.34 mm
Wavelength:Mo Kα radiation (0.71073 Å)
μ:2.9 cm−1
Diffractometer, scan mode:Bruker APEX-II, φ and ω
2θmax, completeness:55°, >99%
N(hkl)measured, N(hkl)unique, Rint:18387, 4883, 0.041
Criterion for Iobs, N(hkl)gt:Iobs > 2 σ(Iobs), 3483
N(param)refined:257
Programs:SHELX [32], Bruker programs [33]
Table 2

Fractional atomic coordinates and isotropic or equivalent isotropic displacement parameters (Å2).

AtomxyzUiso*/Ueq
Cl10.35386(12)0.25966(7)0.81108(8)0.0840(3)
S10.74453(7)0.64574(5)0.76585(5)0.04242(17)
N10.5284(2)0.71345(15)0.63081(14)0.0363(4)
N20.3577(2)0.64492(16)0.74092(14)0.0412(4)
C10.4607(3)0.7930(2)0.48916(19)0.0474(5)
H1A0.54280.74270.44620.057*
H1B0.54170.86890.53590.057*
C20.3050(3)0.8142(2)0.4111(2)0.0539(6)
H2A0.36590.85280.36420.065*
C30.1829(4)0.6971(2)0.33911(19)0.0582(7)
H3A0.08200.71010.28870.070*
H3B0.26280.64650.29460.070*
C40.0929(3)0.6370(2)0.4092(2)0.0521(6)
H4A0.01280.56010.36120.062*
C50.2475(3)0.61608(18)0.48742(18)0.0427(5)
H5A0.18730.57640.53280.051*
H5B0.32850.56450.44490.051*
C60.3703(3)0.73327(16)0.56108(15)0.0327(4)
C70.2463(3)0.8132(2)0.62741(18)0.0493(6)
H7A0.32580.88970.67400.059*
H7B0.18820.77660.67560.059*
C80.0886(4)0.8323(2)0.5487(2)0.0598(7)
H8A0.00520.88290.59190.072*
C9−0.0311(3)0.7146(3)0.4759(2)0.0614(7)
H9A−0.09110.67540.52170.074*
H9B−0.13390.72710.42630.074*
C100.1821(4)0.8939(2)0.4782(2)0.0653(7)
H10A0.08260.90960.42890.078*
H10B0.26210.96990.52570.078*
C110.5148(3)0.66702(16)0.70927(15)0.0337(4)
C120.7813(3)0.76904(19)0.89527(17)0.0443(5)
H12A0.67440.75950.93480.053*
H12B0.90050.76860.94110.053*
C130.7939(3)0.88483(18)0.87905(16)0.0431(5)
C140.9561(5)0.9309(2)0.8505(2)0.0732(8)
H14A1.06180.89110.84350.088*
C150.9643(8)1.0352(3)0.8322(3)0.1201(19)
H15A1.07551.06600.81090.144*
C160.8166(11)1.0949(3)0.8442(3)0.136(3)
H16A0.82571.16780.83300.164*
C170.6540(8)1.0492(3)0.8724(3)0.1100(15)
H17A0.54901.08960.87940.132*
C180.6432(4)0.9439(2)0.8905(2)0.0685(7)
H18A0.53130.91260.91090.082*
C190.3344(3)0.58260(19)0.81193(17)0.0384(5)
C200.3618(3)0.4667(2)0.78347(18)0.0435(5)
H20A0.40820.42990.71780.052*
C210.3212(3)0.4058(2)0.8511(2)0.0508(6)
C220.2558(4)0.4555(3)0.9473(2)0.0631(7)
H22A0.22940.41190.99310.076*
C230.2298(4)0.5701(3)0.9752(2)0.0638(7)
H23A0.18580.60651.04190.077*
C240.2662(3)0.6337(2)0.9084(2)0.0511(6)
H24A0.24460.71240.92840.061*
H1N10.642(3)0.7350(19)0.6208(17)0.039(6)*

Source of material

Benzyl bromide (342 mg, 2.0 mmol) and anhydrous potassium carbonate (277 mg, 2.0 mmol) were added to a solution 1-(adamantan-1-yl)-3-(3-chlorophenyl)thiourea (642 mg, 2.0 mmol), in acetone (10 mL), and the mixture was heated under reflux for 3 h. The solvent was distilled off in vacuo, and the residue was washed with water, dried and recrystallized from ethanol to yield 625 mg (76%) of the title compound as transparent block crystals. M.P.: 367–369 K. Single crystals were obtained by slow evaporation of a EtOH/CHCl3 (1:1) solution at room temperature. 1H-NMR (DMSO-d6, 700.17 MHz): δ 1.58–1.60 (m, 6H, adamantane-H), 1.98–2.0 (s, 9H, adamantane-H), 6.17 (s, 1H, NH), 6.50–6.54 (m, 2H, Ar—H, 6.92–6.93 (m, 1H, Ar—H), 7.16–7.18 (m, 1H, Ar—H), 7.27–7.30 (m, 5H, Ar—H). 13C-NMR (DMSO-d6, 176.08 MHz): δ 29.38, 36.09, 36.57, 41.10 (adamantane-C), 53.76 (benzylic CH2), 121.27, 121.51, 122.01, 127.26, 128.83, 129.27, 130.36, 133.10, 138.05, 148.38 (Ar—C), 152.16 (C = N). ESI-MS, m/z: 410.4 (M + H, 100%)+, 411.4 (M + 2 + H, 35%)+.

Experimental details

Carbon-bound hydrogen atoms were placed in calculated positions and were included in the refinement in the riding model approximation, with Uiso(H) set to 1.2Ueq(C).

The coordinates and the Uiso parameter of the hydrogen atom at the NH group were refined freely.

Discussion

Isothiourea derivatives were early recognized as compounds of particular value in medicinal chemistry. Several substituted isothiourea derivatives were reported to possess significant cardiovascular properties as nitric oxide synthase inhibitors [1], [2], [3], [4], [5], and calcium channel blockers [6]. Isothiourea derivatives were also reported to display potent antimicrobial [7, 8] , anticancer [9, 10] , and anti-anthelmintic [11] activities. The incorporation of the highly lipophilic adamantyl group positively modulates the therapeutic index of several compounds through various mechanisms [12, 13] . Various adamantane derivatives are known for their antiviral activity against the influenza A [14], [15], [16], human immunodeficiency (HIV) [17], [18], [19] and herpes simplex [20] viruses. Moreover, several adamantane-based drugs are currently used as useful therapies for the control central nervous disorders [21, 22] . In addition, potent antimicrobial [23], [24], [25], anticancer [26, 27] , anti-inflammatory [28, 29] and hypoglycemic [30] activities were reported for numerous adamantane-based derivatives. The present investigation describes the synthesis and the single crystal X-ray structural characteristics of the title adamantane-isothiourea hybrid molecule as potential chemotherapeutic agent.

The asymmetric unit of the title structure contains one independent molecule. The N2—C11 bond length is 1.272(3) Å which is typical carbon-nitrogen double bond, The molecule has a Z-configuration around this double bond (cf. the figure). All geometric parameters are in the expected ranges. The molecules are packed in the crystal structure without any intermolecular hydrogen bonds.

Acknowledgement

The authors would like to extend their sincere appreciation to the Deanship of Scientific Research at King Saud University for funding this work through the Research Group Project No. RG-1435-062.

References

1 Shearer, B. G.; Lee, S.; Oplinger, J. A.; Frick, L. W.; Garvey, E. P.; Furfine, E. S.: Substituted N-phenylisothioureas: potent inhibitors of human nitric oxide synthase with neuronal isoform selectivity. J. Med. Chem. 40 (1997) 1901–1905.10.1021/jm960785cSuche in Google Scholar PubMed

2 Vromen, A.; Szabo, C.; Southan, G. J.; Salzman, A. L.: Effects of S-isopropyl isothiourea, a potent inhibitor of nitric oxide synthase, in severe hemorrhagic shock. J. Appl. Physiol. 81 (1996) 707–715.10.1152/jappl.1996.81.2.707Suche in Google Scholar PubMed

3 Castaño, T.; Encinas, A.; Pérez, C.; Castro, A.; Campillo, N. E.; Gil, C.: Design, synthesis, and evaluation of potential inhibitors of nitric oxide synthase. Bioorg. Med. Chem. 16 (2008) 6193–6206.10.1016/j.bmc.2008.04.036Suche in Google Scholar PubMed

4 Cooper, G. R.; Mialkowski, K.; Wolff, D. J.: Cellular and enzymatic studies of N(omega)-propyl-l-arginine and S-ethyl-N-[4-(trifluoromethyl)phenyl]isothiourea as reversible, slowly dissociating inhibitors selective for the neuronal nitric oxide synthase isoform. Arch. Biochem. Biophys. 375 (2000) 183–194.10.1006/abbi.1999.1658Suche in Google Scholar PubMed

5 Kazimierczuk, Z.; Chalimoniuk, M.; Laudy, A. E.; Moo-Puc, R.; Cedillo-Rivera, R.; Starosciak, B. J.; Chrapusta, S. J.: Synthesis and antimicrobial and nitric oxide synthase inhibitory activities of novel isothiourea derivatives. Arch. Pharmacal. Res. 33 (2010) 821–830.10.1007/s12272-010-0604-8Suche in Google Scholar PubMed

6 Barrientos, G.; Bose, D. D.; Feng, W.; Padilla, I.; Pessah, I. N.: The Na+/Ca2+ exchange inhibitor 2-(2-(4-(4-nitrobenzyloxy)phenyl)ethyl)isothiourea methanesulfonate (KBR7943) also blocks ryanodine receptors type 1 (RyR1) and type 2 (RyR2) channels. Mol. Pharmacol. 76 (2009) 560–568.10.1124/mol.109.057265Suche in Google Scholar PubMed PubMed Central

7 Shelke, S. H.; Mhaske, P. C.; Hande, P.; Bobade, V. D.: Synthesis and antimicrobial activities of novel series of 1-((4-methyl-2-substituted thiazol-5-yl)methyleneam INO)-2-substituted isothiourea derivatives. Phosphorus Sulfur Silicon Rel. Elem. 188 (2013) 1262–1270.10.1080/10426507.2012.745542Suche in Google Scholar

8 Nicholson, A.; Perry, J. D.; James, A. L.; Stanforth, S. P.; Carnell, S.; Wilkinson, K.; Anjam Khan, C. M.; De Soyza, A.; Gould, F. K.: In vitro activity of S-(3,4-dichlorobenzyl)isothiourea hydrochloride and novel structurally related compounds against multidrug-resistant bacteria, including Pseudomonas aeruginosa and Burkholderia cepacia complex. Int. J. Antimicrob. Agents 39 (2012) 27–32.10.1016/j.ijantimicag.2011.08.015Suche in Google Scholar PubMed

9 Korokiewicz, M.; Romiszewska, A.; Chilmonczyk, Z.; Kazimierczuk, Z.: New benzimidazole-derived isothioureas as potential antileukemic agents − Studies in vitro. Med. Chem. 11 (2015) 364–372.10.2174/1573406410666141203124329Suche in Google Scholar PubMed

10 Koronkiewicz, M.; Chilmonczyk, Z.; Kazimierczuk, Z.: Proapoptotic effects of novel pentabromobenzylisothioureas in human leukemia cell lines. Med. Chem. Res. 21 (2012) 3111–3118.10.1007/s00044-011-9841-8Suche in Google Scholar PubMed PubMed Central

11 Brewer, M. D.; Dorgan, R. J.; Manger, B. R.; Mamalis, P.; Webster, R. A.: Isothiourea derivatives of 6-phenyl-2,3,5,6-tetrahydroimidazo[2,1-b]thiazole with broad-spectrum anthelmintic activity. J. Med. Chem. 30 (1987) 1848–1853.10.1021/jm00393a028Suche in Google Scholar

12 Lamoureux, G.; Artavia, G.: Use of the adamantane structure in medicinal chemistry. Curr. Med. Chem. 17 (2010) 2967–2978.10.2174/092986710792065027Suche in Google Scholar

13 Liu, J.; Obando, D.; Liao, V.; Lifa, T.; Codd, R.: The many faces of the adamantyl group in drug design. Eur. J. Med. Chem. 46 (2011) 1949–1963.10.1016/j.ejmech.2011.01.047Suche in Google Scholar

14 Togo, Y.; Hornick, R. B.; Dawkins, A. T.: Studies on induced influenza in man. I. Double blind studies designed to assess prophylactic efficacy of amantadine hydrochloride against A2/Rockville/1/65 strain. J. Am. Med. Assoc. 203 (1968) 1089–1094.10.1001/jama.203.13.1089Suche in Google Scholar

15 Davies, W. L.; Grunnert, R. R.; Haff, R. F.; McGahen, J. W.; Neumeyer, E. M.; Paulshock, M.; Watts, J. C.; Wood, T. R.; Hermann, E. C.; Hoffmann, C. E.: Antiviral activity of 1-adamantamine (amantadine). Science 144 (1964) 862–863.10.1126/science.144.3620.862Suche in Google Scholar

16 Wendel, H. A.; Snyder, M. T. Pell, S.: Trial of amantadine in epidemic influenza. Clin. Pharmacol. Therap. 7 (1966) 38–43.10.1002/cpt19667138Suche in Google Scholar

17 Burstein, M. E.; Serbin, A. V.; Khakhulina, T. V.; Alymova, I. V.; Stotskaya, L. L.; Bogdan, O. P.; Manukchina, E. E.; Jdanov, V. V.; Sharova, N. K.: Inhibition of HIV-1 replication by newly developed adamantane-containing polyanionic agents. Antiviral Res. 41 (1999) 135–144.10.1016/S0166-3542(99)00006-6Suche in Google Scholar

18 Balzarini, J.; Orzeszko, B.; Mauri, J. K.; Orzeszko, A.: Synthesis and anti-HIV studies of 2-adamantyl-substituted thiazolidin-4-ones. Eur. J. Med. Chem. 42 (2007) 993–1003.10.1016/j.ejmech.2007.01.003Suche in Google Scholar PubMed

19 El-Emam, A. A.; Al-Deeb, O. A.; Al-Omar, M. A.; Lehmann, J.: Synthesis, antimicrobial, and anti-HIV-1 activity of certain 5-(1-adamantyl)-2-substituted thio-1,3,4-oxadiazoles and 5-(1-adamantyl)-3-substituted aminomethyl-1,3,4-oxadiazoline-2-thiones. Bioorg. Med. Chem. 12 (2004) 5107–5113.10.1016/j.bmc.2004.07.033Suche in Google Scholar PubMed

20 Rosenthal, K. S.; Sokol, M. S.; Ingram, R. L.; Subramanian, R.; Fort, R. C.: Tromantadine: Inhibitor of early and late events in herpes simplex virus replication. Antimicrob. Agents Chemother. 22 (1982) 1031–1036.10.1128/AAC.22.6.1031Suche in Google Scholar PubMed PubMed Central

21 Bormann, J.: Memantine is a potent blocker of N-methyl-D-aspartate (NMDA) receptor channels. Eur. J. Pharmacol. 166 (1989) 591–592.10.1016/0014-2999(89)90385-3Suche in Google Scholar

22 Abou-Gharbia, M. A.; Childers, W. E., Jr.; Fletcher, H.; McGaughey, G.; Patel, U.; Webb, M. B.; Yardley, J.; Andree, T.; Boast, C.; Kucharik, R. J., Jr.; Marquis, K.; Morris, H.; Scerni, R.; Moyer, J. A.: Synthesis and SAR of adatanserin: novel adamantly aryl- and heteroarylpiperazines with dual serotonin 5-HT1A and 5-HT2 activity as potential anxiolytic and antidepressant agents. J. Med. Chem. 42 (1999) 5077–5094.10.1021/jm9806704Suche in Google Scholar PubMed

23 Jia, L.; Tomaszewski, J. E.; Hanrahan, C.; Coward, L.; Noker, P.; Gorman, G.; Nikonenko, B.; Protopopova, M.: Pharmacodynamics and pharmacokinetics of SQ109, a new diamine-based antitubercular drug. Brit. J. Pharmacol. 144 (2005) 80–87.10.1038/sj.bjp.0705984Suche in Google Scholar PubMed PubMed Central

24 Omar, K.; Geronikaki, A.; Zoumpoulakis, P.; Camoutsis, C.; Soković, M.; Ćirić, A.; Glamoćlija, J.: Novel 4-thiazolidinone derivatives as potential antifungal and antibacterial drugs. Bioorg. Med. Chem. 18 (2010) 426–432.10.1016/j.bmc.2009.10.041Suche in Google Scholar PubMed

25 El-Emam, A. A.; Al-Tamimi, A.-M. S.; Al-Omar, M. A.; Alrashood, K. A.; Habib, E. E.: Synthesis and antimicrobial activity of novel 5-(1-adamantyl)-2-aminomethyl-4-substituted-1,2,4-triazoline-3-thiones. Eur. J. Med. Chem. 68 (2013) 96–102.10.1016/j.ejmech.2013.07.024Suche in Google Scholar PubMed

26 Sun, S. Y.; Yue, P.; Chen, X.; Hong, W. K.; Lotan, R.: The synthetic retinoid CD437 selectively induces apoptosis in human lung cancer cells while sparing normal human lung epithelial cells. Cancer Res. 62 (2002) 2430–2436.Suche in Google Scholar

27 Lorenzo, P.; Alvarez, R.; Ortiz, M. A.; Alvarez, S.; Piedrafita, F. J.; de Lira, Á. R.: Inhibition of IκB kinase-β and anticancer activities of novel chalcone adamantyl arotinoids. J. Med. Chem. 51 (2008) 5431–5440.10.1021/jm800285fSuche in Google Scholar PubMed

28 Al-Abdullah, E. S.; Asiri, H. H.; Lahsasni, S.; Habib, E. E.; Ibrahim, T. M.; El-Emam, A. A.: Synthesis, antimicrobial, and anti-inflammatory activity, of novel S-substituted and N-substituted 5-(1-adamantyl)-1,2,4-triazole-3-thiols. Drug Des. Dev. Ther. 8 (2014) 505–518.10.2147/DDDT.S62465Suche in Google Scholar PubMed PubMed Central

29 Al-Deeb, O. A.; Al-Omar, M. A.; El-Brollosy, N. R.; Habib, E. E.; Ibrahim, T. M.; El-Emam, A. A.: Synthesis, antimicrobial, and anti-inflammatory activities of novel 2-[3-(1-adamantyl)-4-substituted-5-thioxo-1,2,4-triazolin-1-yl]acetic acids, 2-[3-(1-adamantyl)-4-substituted-5-thioxo-1,2,4-triazolin-1-yl]propionic acids and related derivatives. Arzneim.-Forsch./Drug Res. 56 (2006) 40–47.10.1055/s-0031-1296699Suche in Google Scholar PubMed

30 Augeri, D. J.; Robl, J. A.; Betebenner, D. A.; Magnin, D. R.; Khanna, A.; Robertson, J. G.; Wang, A.; Simpkins, L. M.; Taunk, P.; Huang, Q.; Han, S.; Abboa-Offei, B.; Cap, M.; Xin, L.; Tao, L.; Tozzo, E.; Welzel, G. E.; Egan, D. M.; Marcinkeviciene, J.; Chang, S. Y.; Biller, S. A.; Kirby, M. S.; Parker, R. A.; Hamann, L. G.: Discovery and preclinical profile of saxagliptin (BMS-477118): A highly potent, long-acting, orally active dipeptidyl peptidase IV inhibitor for the treatment of type 2 diabetes. J. Med. Chem. 48 (2005) 5025–5037.10.1021/jm050261pSuche in Google Scholar PubMed

31 Sheldrick, G. M.: A short history of SHELX. Acta Crystallogr. A64 (2008) 112–122.10.1107/S0108767307043930Suche in Google Scholar PubMed

32 Brucker. APEX2, SAINT and SADABS. Brucker AXS Inc., Madison, Wisconsin, USA, (2009).Suche in Google Scholar

Received: 2016-10-12
Accepted: 2017-3-5
Published Online: 2017-3-23
Published in Print: 2017-5-24

©2017 Ali A. El-Emam et al., published by De Gruyter, Berlin/Boston

This work is licensed under the Creative Commons Attribution-NonCommercial-NoDerivatives 3.0 License.

Artikel in diesem Heft

  1. Cover and Frontmatter
  2. Crystal structure of 2,5-diiodo-4-nitro-1H-imidazole hemihydrate, C6H4I4N6O5
  3. Crystal structure of catena-poly[μ2-2,2′-(1,3-phenylene)diacetato-κ4O,O′:O′′,O′′′)-(μ2-1,6-bis(2-methyl-1H-benzo[d]imidazol-1-yl)hexane-κ2N:N′)cadmium(II)], C32H34CdN4O4
  4. Crystal structure of poly[aqua-(2,2′-bipyridine-κN,N′)-(μ4-5,5′-(hexane-1,6-diyl)-bis(oxy)diisophthalato κ8O1,O2:O3,O4:O5,O6:O7,O8)manganese(II)], C21H21MnN2O7
  5. Crystal structure of poly-[(μ2-((1,3-bis(benzimidazol-1-yl)propane-κ2N:N′)(μ2-4-tert-butyl-phthalato-κ2O:O′)cobalt(II)] monohydrate, C29H30CoN4O5
  6. Crystal structure of 2-amino-4-(3,4,5-trimethoxy-phenyl)-5-(oxo-5,6,7,8-tetrahydro-4H-chromene)-3-carbonitrile – ethanol (1/1), C21H26N2O6
  7. Crystal structure of ethyl 1-benzyl-5-phenyl-1H-pyrazole-3-carboxylate, C19H18N2O2
  8. Crystal structure of 2-(1-benzyl-3-phenyl-1H-pyrazol-5-yl)-5-(4-nitrobenzylthio)-1,3,4-oxadiazole, C25H19N5O3S
  9. Structure and photochromism of 1,2-bis[2-methyl-5-(2-chlorophenyl)-3-thienyl]-3,3,4,4,5,5-hexafluorocyclopent-1-ene, C27H16Cl2F6S2
  10. The crystal structure of the Schiff base (E)-2,6-diisopropyl-N-(pyridin-4-ylmethylene)aniline, C18H22N2
  11. Crystal structure of (E)-2,4-dibromo-6-(((4-methyl-2-nitrophenyl)imino) methyl)phenol, C10H14Br2N2O3
  12. Crystal structure of (bis(2,2′-bipyridine-κ2N,N′))-(3,5-dinitrosalicylato-κ2O,O′)nickel(II), C27H18N6NiO7
  13. Crystal structure of 1-(diethoxy phosphonomethyl) 2-benzoyl-3-chloro-2-cyclohexen-1-ol, C18H24ClO5P
  14. Crystal structure of tetraaqua-bis(1,3-benzimidazol-3-ium-1,3-diacetato-κO)copper(II) hemihydrate, C22H27CuN4O12.50
  15. Crystal structure of 1α,11-dihydroxyeremophil-9-en-8-one, C15H24O3
  16. Crystal structure of 1-ferrocenylsulfonyl-1H-imidazo[4,5-b]pyridine, C16H13FeN3O2S
  17. Crystal structure of bis(μ2-azido-κ2N:N)-dichlorido-bis(μ2-2-(pyridin-2-yl)ethan-1-ol-κ2O,N)dicopper(II), C14H18Cl2Cu2N8O2
  18. Crystal structure of (5,15-cis-bis(2-hydroxy-1-naphthyl)-10-phenyl-20-(4-hydroxyphenyl)-porphyrinato)-(pyridine)-zinc(ii) pyridine solvate, C67H47N7O3Zn
  19. Crystal structure of (μ2-[2,2′-bis(diphenylphosphino)-1,1′-binaphthalene oxide-κ2O,P])-iodido copper(I), C44H32CuIOP2
  20. Crystal structure of 6,8-diphenyl-2-(4-fluorophenyl)-2,3-dihydroquinolin-4(3H)-one, C27H20FNO
  21. Crystal structure of 5,11,17,23-tetra(tert-butyl)-25,26,27,28-tetrahexoxycalix[4]arene, C68H104O4
  22. Crystal structure of N,N′–bis(pyridin-4-ylmethyl)pyrazine-2,3-dicarboxamide dihydrate, C18H20N6O4
  23. Crystal structure of a diaqua-bis(3,5-di(1H-imidazol-1-yl)pyridine-κN)-bis(2-(4-carboxy-phenyl)acetato-κO]manganese(II), C40H36MnN10O10
  24. Crystal structure of 4-(4-hydroxy-3-methoxy-phenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylic acid methyl ester, C21H25NO5
  25. Crystal structure of (E)-4,4′-(ethene-1,2-diyl)bis(3-nitrobenzoic acid) 1.5 hydrate, C16H13N2O9.5
  26. Crystal structure of (E)-2-(5-(4-fluorophenyl)-3-(furan-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)-5-((4-fluorophenyl)diazenyl)-4-methylthiazole, C23H17F2N5OS
  27. Crystal structure of the co-crystalline adduct 4-((4,4-dimethyl-2,6-dioxocyclohexylidene)methylamino)-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide - acetic acid (1/1), C21H24N4O4S ⋅ C2H4O2
  28. Synthesis and crystal structure of 2-((5-chlorobenzo[c][1,2,5]thiadiazol-4-yl)amino)-4,5-dihydro-1H-imidazol-3-ium tetraphenylborate, C33H29BClN5S
  29. Crystal structure of (4-chlorophenyl)(3-ferrocenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)methanone, C21H14ClF3FeN2O
  30. Crystal structure of (S)-benzyl 3-(benzylcarba-moyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate, C25H24N2O3
  31. Crystal structure of 5-acetyl-3-(3-fluoro-4-morpholinophenyl)oxazolidin-2-one, C15H17FN2O4
  32. Crystal structure of 2-(4-fluorophenyl)-1,3-dimethyl-1H-perimidin-3-ium iodide, C19H16FIN2
  33. Crystal structure of methyl 1H-indole-2-carboxylate, C10H9NO2
  34. Crystal structure of 2,3-diphenyl-1-[(dipropylamino)acetyl]-1,3-diazaspiro[4.5]decan-4-one, C28H37N3O2
  35. Crystal structure of 1-(2H-1,3-benzodioxol-5-yl)-3-(1H-imidazol-1-yl)propan-1-one, C13H12N2O3
  36. Crystal structure of 2,9-dibromo-1,10-phenanthroline, C12H6Br2N2
  37. Crystal structure of 3-(adamantan-1-yl)-4-(4-fluorophenyl)-1H-1,2,4-triazole-5(4H)-thione, C18H20FN3S
  38. Crystal structure of trans-bis((E)-7-oxo-4-(phenyldiazenyl)cyclohepta-1,3,5-trien-1-olato)-κ2O,O′)-bis(pyridine-κN)cobalt(II), C36H28CoN6O4
  39. Crystal structure of 2-(4-methyl-3-phenylthiazol-2(3H)-ylidene)malononitrile, C13H9N3S
  40. Crystal structure of (Z)-3-(adamantan-1-yl)-1-(3-chlorophenyl)-S-benzylisothiourea, C24H27ClN2S
  41. Crystal structure of chlorido{[3-(η5-cyclopenta-dienyl)-2,2,3-trimethyl-1-phenylbutylidene] azanido-κN}[η2(N,O)-N,N-dimethylhydroxylaminato]titanium(IV), C20H27ClN2OTi
  42. Crystal Structure of 1,1′-dimethyl-[4,4′-bipyridine]-1,1′-diium tetrachloridozincate(II), C12H14Cl4N2Zn
  43. Crystal structure of 5-nitro-2-(pyrrolidin-1-yl)benzaldehyde, C11H12N2O3
  44. Crystal structure of 2,3-diphenyl-1-(morpholin-4-ylacetyl)-1,3-diazaspiro[4.5]decan-4-one, C26H31N3O3
  45. Crystal structure of 3,3-dimethyl-3,4-dihydro-1H-benzo[c]chromene-1,6(2H)-dione, C15H14O3
  46. Crystal structure of bis(2-(2-hydroxymethyl)pyridine-κ2N,O)-bis(pivalato-κO)nickel(II), C22H32N2NiO6
  47. Crystal structure of (1,10-phenanthroline-κ2N,N′)-bis(1H-pyrazole-3-carboxylato-κ2N,O)manganese(II) trihydrate, C20H20N6O7Mn
  48. The crystal structure of 3-aminopropan-1-aminium iodide, C3H11N2I
  49. Crystal structure of ethyl 1-(4-chlorophenyl)-5-methyl-1H-1,2,3-triazole-4 carboxylate, C12H12ClN3O2
  50. Crystal structure of 4,4′-((1Z,1′Z)-2,2′-(2,5-diethoxy-1,4-phenylene)bis(ethene-2,1-diyl))dipyridine, C24H24N2O2
  51. Crystal structure of (16S)-12,16-epoxy-11,14-dihydroxy-17(15/16)-abeo-3a,18-cyclo-8,11,13-abietatrien-7-one, C20H24O4
  52. Crystal structure of aquadichlorido(2,4,6-tri-2-pyridyl-1,3,5-triazine-κ3N,N′,N′′)nickel(II) monohydrate, C18H16Cl2N6NiO2
  53. Crystal structure of catena-poly[dichlorido-(μ-ethane-1,2-diyl-bis-(pyridyl-4-carboxylate-κN:N′)mercury(II)], C15H14Cl2HgN2O4
  54. Crystal structure of methyl 2-acetamido-5-chlorbenzoate, C10H10ClNO3
  55. Crystal structure of tetrakis(μ2-3,3-dimethylacrylato-κ2O,O′)-bis(2-aminopyrimidine-κN) dicopper(II), C28H38Cu2N6O8
  56. Crystal structure of 3-amino-8-methoxy-1-phenyl-1H-benzo[f]chromene-2-carbonitrile, C21H16N2O2
  57. Crystal structure of 4-(2-ammonioethyl)morpholin-4-ium dichloride monohydrate, C6H18Cl2N2O2
  58. Crystal structure of 1-(3-((5-bromo-2-hydroxybenzylidene)amino)phenyl)ethanone O-benzyl oxime, C22H19BrN2O2
  59. Crystal structure of 2-(4-(dimethylamino)-2-fluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol monohydrate, C15H20FN7O2
  60. Crystal structure of 4-bromo-2-(1H-pyrazol-3-yl)phenol, C9H7BrN2O
  61. Crystal structure of 1,2,3,4,5-pentamethyl-1,3-cyclopentadiene, C10H16
https://doi.org/10.1515/ncrs-2016-0315
Creative Commons
BY-NC-ND 3.0

Artikel in diesem Heft

  1. Cover and Frontmatter
  2. Crystal structure of 2,5-diiodo-4-nitro-1H-imidazole hemihydrate, C6H4I4N6O5
  3. Crystal structure of catena-poly[μ2-2,2′-(1,3-phenylene)diacetato-κ4O,O′:O′′,O′′′)-(μ2-1,6-bis(2-methyl-1H-benzo[d]imidazol-1-yl)hexane-κ2N:N′)cadmium(II)], C32H34CdN4O4
  4. Crystal structure of poly[aqua-(2,2′-bipyridine-κN,N′)-(μ4-5,5′-(hexane-1,6-diyl)-bis(oxy)diisophthalato κ8O1,O2:O3,O4:O5,O6:O7,O8)manganese(II)], C21H21MnN2O7
  5. Crystal structure of poly-[(μ2-((1,3-bis(benzimidazol-1-yl)propane-κ2N:N′)(μ2-4-tert-butyl-phthalato-κ2O:O′)cobalt(II)] monohydrate, C29H30CoN4O5
  6. Crystal structure of 2-amino-4-(3,4,5-trimethoxy-phenyl)-5-(oxo-5,6,7,8-tetrahydro-4H-chromene)-3-carbonitrile – ethanol (1/1), C21H26N2O6
  7. Crystal structure of ethyl 1-benzyl-5-phenyl-1H-pyrazole-3-carboxylate, C19H18N2O2
  8. Crystal structure of 2-(1-benzyl-3-phenyl-1H-pyrazol-5-yl)-5-(4-nitrobenzylthio)-1,3,4-oxadiazole, C25H19N5O3S
  9. Structure and photochromism of 1,2-bis[2-methyl-5-(2-chlorophenyl)-3-thienyl]-3,3,4,4,5,5-hexafluorocyclopent-1-ene, C27H16Cl2F6S2
  10. The crystal structure of the Schiff base (E)-2,6-diisopropyl-N-(pyridin-4-ylmethylene)aniline, C18H22N2
  11. Crystal structure of (E)-2,4-dibromo-6-(((4-methyl-2-nitrophenyl)imino) methyl)phenol, C10H14Br2N2O3
  12. Crystal structure of (bis(2,2′-bipyridine-κ2N,N′))-(3,5-dinitrosalicylato-κ2O,O′)nickel(II), C27H18N6NiO7
  13. Crystal structure of 1-(diethoxy phosphonomethyl) 2-benzoyl-3-chloro-2-cyclohexen-1-ol, C18H24ClO5P
  14. Crystal structure of tetraaqua-bis(1,3-benzimidazol-3-ium-1,3-diacetato-κO)copper(II) hemihydrate, C22H27CuN4O12.50
  15. Crystal structure of 1α,11-dihydroxyeremophil-9-en-8-one, C15H24O3
  16. Crystal structure of 1-ferrocenylsulfonyl-1H-imidazo[4,5-b]pyridine, C16H13FeN3O2S
  17. Crystal structure of bis(μ2-azido-κ2N:N)-dichlorido-bis(μ2-2-(pyridin-2-yl)ethan-1-ol-κ2O,N)dicopper(II), C14H18Cl2Cu2N8O2
  18. Crystal structure of (5,15-cis-bis(2-hydroxy-1-naphthyl)-10-phenyl-20-(4-hydroxyphenyl)-porphyrinato)-(pyridine)-zinc(ii) pyridine solvate, C67H47N7O3Zn
  19. Crystal structure of (μ2-[2,2′-bis(diphenylphosphino)-1,1′-binaphthalene oxide-κ2O,P])-iodido copper(I), C44H32CuIOP2
  20. Crystal structure of 6,8-diphenyl-2-(4-fluorophenyl)-2,3-dihydroquinolin-4(3H)-one, C27H20FNO
  21. Crystal structure of 5,11,17,23-tetra(tert-butyl)-25,26,27,28-tetrahexoxycalix[4]arene, C68H104O4
  22. Crystal structure of N,N′–bis(pyridin-4-ylmethyl)pyrazine-2,3-dicarboxamide dihydrate, C18H20N6O4
  23. Crystal structure of a diaqua-bis(3,5-di(1H-imidazol-1-yl)pyridine-κN)-bis(2-(4-carboxy-phenyl)acetato-κO]manganese(II), C40H36MnN10O10
  24. Crystal structure of 4-(4-hydroxy-3-methoxy-phenyl)-2,7,7-trimethyl-5-oxo-1,4,5,6,7,8-hexahydro-quinoline-3-carboxylic acid methyl ester, C21H25NO5
  25. Crystal structure of (E)-4,4′-(ethene-1,2-diyl)bis(3-nitrobenzoic acid) 1.5 hydrate, C16H13N2O9.5
  26. Crystal structure of (E)-2-(5-(4-fluorophenyl)-3-(furan-2-yl)-4,5-dihydro-1H-pyrazol-1-yl)-5-((4-fluorophenyl)diazenyl)-4-methylthiazole, C23H17F2N5OS
  27. Crystal structure of the co-crystalline adduct 4-((4,4-dimethyl-2,6-dioxocyclohexylidene)methylamino)-N-(4,6-dimethylpyrimidin-2-yl)benzenesulfonamide - acetic acid (1/1), C21H24N4O4S ⋅ C2H4O2
  28. Synthesis and crystal structure of 2-((5-chlorobenzo[c][1,2,5]thiadiazol-4-yl)amino)-4,5-dihydro-1H-imidazol-3-ium tetraphenylborate, C33H29BClN5S
  29. Crystal structure of (4-chlorophenyl)(3-ferrocenyl-5-(trifluoromethyl)-1H-pyrazol-1-yl)methanone, C21H14ClF3FeN2O
  30. Crystal structure of (S)-benzyl 3-(benzylcarba-moyl)-3,4-dihydroisoquinoline-2(1H)-carboxylate, C25H24N2O3
  31. Crystal structure of 5-acetyl-3-(3-fluoro-4-morpholinophenyl)oxazolidin-2-one, C15H17FN2O4
  32. Crystal structure of 2-(4-fluorophenyl)-1,3-dimethyl-1H-perimidin-3-ium iodide, C19H16FIN2
  33. Crystal structure of methyl 1H-indole-2-carboxylate, C10H9NO2
  34. Crystal structure of 2,3-diphenyl-1-[(dipropylamino)acetyl]-1,3-diazaspiro[4.5]decan-4-one, C28H37N3O2
  35. Crystal structure of 1-(2H-1,3-benzodioxol-5-yl)-3-(1H-imidazol-1-yl)propan-1-one, C13H12N2O3
  36. Crystal structure of 2,9-dibromo-1,10-phenanthroline, C12H6Br2N2
  37. Crystal structure of 3-(adamantan-1-yl)-4-(4-fluorophenyl)-1H-1,2,4-triazole-5(4H)-thione, C18H20FN3S
  38. Crystal structure of trans-bis((E)-7-oxo-4-(phenyldiazenyl)cyclohepta-1,3,5-trien-1-olato)-κ2O,O′)-bis(pyridine-κN)cobalt(II), C36H28CoN6O4
  39. Crystal structure of 2-(4-methyl-3-phenylthiazol-2(3H)-ylidene)malononitrile, C13H9N3S
  40. Crystal structure of (Z)-3-(adamantan-1-yl)-1-(3-chlorophenyl)-S-benzylisothiourea, C24H27ClN2S
  41. Crystal structure of chlorido{[3-(η5-cyclopenta-dienyl)-2,2,3-trimethyl-1-phenylbutylidene] azanido-κN}[η2(N,O)-N,N-dimethylhydroxylaminato]titanium(IV), C20H27ClN2OTi
  42. Crystal Structure of 1,1′-dimethyl-[4,4′-bipyridine]-1,1′-diium tetrachloridozincate(II), C12H14Cl4N2Zn
  43. Crystal structure of 5-nitro-2-(pyrrolidin-1-yl)benzaldehyde, C11H12N2O3
  44. Crystal structure of 2,3-diphenyl-1-(morpholin-4-ylacetyl)-1,3-diazaspiro[4.5]decan-4-one, C26H31N3O3
  45. Crystal structure of 3,3-dimethyl-3,4-dihydro-1H-benzo[c]chromene-1,6(2H)-dione, C15H14O3
  46. Crystal structure of bis(2-(2-hydroxymethyl)pyridine-κ2N,O)-bis(pivalato-κO)nickel(II), C22H32N2NiO6
  47. Crystal structure of (1,10-phenanthroline-κ2N,N′)-bis(1H-pyrazole-3-carboxylato-κ2N,O)manganese(II) trihydrate, C20H20N6O7Mn
  48. The crystal structure of 3-aminopropan-1-aminium iodide, C3H11N2I
  49. Crystal structure of ethyl 1-(4-chlorophenyl)-5-methyl-1H-1,2,3-triazole-4 carboxylate, C12H12ClN3O2
  50. Crystal structure of 4,4′-((1Z,1′Z)-2,2′-(2,5-diethoxy-1,4-phenylene)bis(ethene-2,1-diyl))dipyridine, C24H24N2O2
  51. Crystal structure of (16S)-12,16-epoxy-11,14-dihydroxy-17(15/16)-abeo-3a,18-cyclo-8,11,13-abietatrien-7-one, C20H24O4
  52. Crystal structure of aquadichlorido(2,4,6-tri-2-pyridyl-1,3,5-triazine-κ3N,N′,N′′)nickel(II) monohydrate, C18H16Cl2N6NiO2
  53. Crystal structure of catena-poly[dichlorido-(μ-ethane-1,2-diyl-bis-(pyridyl-4-carboxylate-κN:N′)mercury(II)], C15H14Cl2HgN2O4
  54. Crystal structure of methyl 2-acetamido-5-chlorbenzoate, C10H10ClNO3
  55. Crystal structure of tetrakis(μ2-3,3-dimethylacrylato-κ2O,O′)-bis(2-aminopyrimidine-κN) dicopper(II), C28H38Cu2N6O8
  56. Crystal structure of 3-amino-8-methoxy-1-phenyl-1H-benzo[f]chromene-2-carbonitrile, C21H16N2O2
  57. Crystal structure of 4-(2-ammonioethyl)morpholin-4-ium dichloride monohydrate, C6H18Cl2N2O2
  58. Crystal structure of 1-(3-((5-bromo-2-hydroxybenzylidene)amino)phenyl)ethanone O-benzyl oxime, C22H19BrN2O2
  59. Crystal structure of 2-(4-(dimethylamino)-2-fluorophenyl)-1,3-bis(1H-1,2,4-triazol-1-yl)propan-2-ol monohydrate, C15H20FN7O2
  60. Crystal structure of 4-bromo-2-(1H-pyrazol-3-yl)phenol, C9H7BrN2O
  61. Crystal structure of 1,2,3,4,5-pentamethyl-1,3-cyclopentadiene, C10H16
Jetzt anmelden und 20% sparen
Institutioneller Zugang
Wie funktioniert Authentifizierung?
Haben Sie eine Idee, wie wir unsere Website verbessern können?
Bitte schreiben Sie uns.
© 2025 De Gruyter Brill
Heruntergeladen am 1.10.2025 von https://www.degruyterbrill.com/document/doi/10.1515/ncrs-2016-0315/html?srsltid=AfmBOoosSzlo3wsxNGP77Py7zKbbpLMlkHbL6PKB4zUswSgyOFiJr8ao
Button zum nach oben scrollen